drugset / Trial / NCT03601923

Niraparib in Patients With Pancreatic Cancer

NCT03601923

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying an investigational therapy as a possible treatment for pancreatic cancer. The drugs involved in this study are: -Niraparib

Timeline

Start
2018-08-22
Primary completion
2025-12-31
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule 200 mg Oral
Subject Niraparib Small molecule 300 mg Oral